About Our Innovation Prize

Boehringer Ingelheim’s Innovation Prize was established in Boston in 2015 to recognize the challenge and dedication of life-science entrepreneurs in advancing new ideas and new science.

The Innovation Prize recognizes the challenge and dedication it takes to start a new company by awarding valuable resources to life-science start-ups, allowing recipients to focus on developing the next generation of breakthrough medicines. Sponsored by Boehringer Ingelheim, the Prize* facilitates business growth, allowing recipients to focus on developing the next generation of breakthrough medicines. The Prize is established in the USA, Japan, China and various innovation ecosystems in Europe, including Austria.

We will announce the next call for the Innovation Prize in this page and through our LinkedIn channel.

Celebrating Our Innovation Prize Winners in Austria

The Innovation Prize Vienna 2024 was awarded to Ablevia Biotech. Ablevia, founded in 2018, has developed an innovative solution for the rapid and selective elimination of harmful antibodies without impeding the immune system. Previous winners included a:head bio in 2021, recognized for its work in growing cerebral organoids to conduct research into therapeutics for central nervous system disorders; and Proxygen in 2020, a startup developing a unique molecular glue degrader discovery platform. Since its inception in 2015, more than 20 companies have been awarded prizes with a value of more than 1,000,000 Euro.

*Prizes are adapted according to location and include, for example, free lab space for one year.

Creating breakthrough medicines that change patients’ lives starts with a commitment to identify the health challenges of the future and advance emerging science. As an independent and family- owned company, we have the freedom to pursue our long- term vision, with distinctive approaches that enable new journeys of discovery today that will transform the lives of patients in generations to come.